Loading...

Teresa De Marco, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Phone415-502-8584
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California IrvineM.D.1982School of Medicine
    University of California, San Francisco, CA2018Diversity, Equity, and Inclusion Champion Training
    Collapse Awards and Honors
    Castle Connolly2011Top Doctors
    UCSF Cardiovascular Research Institute2010Teresa De Marco, MD, Conference Room
    University of California, San Francisco2009R.H. and Jane G. Logan Endowed Chair in Cardiology
    University of California, San Francisco2008Honoree, 500th Thoracic Transplant Celebration
    San Francisco Magazine2005Best Cardiologists in the Bay Area
    University of California, San Francisco2004Exceptional Physician Award
    San Francisco Magazine2003Best Cardiologists in Bay Area
    2001  - 2011Best Doctors in America
    University of California, San Francisco2001Celebrated Faculty Women

    Collapse Overview 
    Collapse Overview
    CLINICAL INTERESTS: Advanced heart failure, cardiomyopathies, heart transplantation, mechanical circulatory support, and pulmonary hypertension
    RESEARCH INTERESTS: Translational research in the diagnosis, prognosis, medical and surgical treatment for the above disease states

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Brondfield MN, Reid MJ, Rutishauser RL, Cope JR, Tang J, Ritter JM, Matanock A, Ali I, Doernberg SB, Hilts-Horeczko A, DeMarco T, Klein L, Babik JM. Disseminated Acanthamoeba infection in a heart transplant recipient treated successfully with a miltefosine-containing regimen: Case report and review of the literature. Transpl Infect Dis. 2017 Apr; 19(2). PMID: 28067969.
      View in: PubMed
    2. Benza RL, Gomberg-Maitland M, Demarco T, Frost AE, Torbicki A, Langleben D, Pulido T, Correa-Jaque P, Passineau MJ, Wiener HW, Tamari M, Hirota T, Kubo M, Tiwari HK. Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015 Dec 01; 192(11):1345-54. PMID: 26252367.
      View in: PubMed
    3. Abraham WT, Anand I, Aranda JM, Boehmer J, Costanzo MR, DeMarco T, Holcomb R, Ivanhoe R, Kolber M, Rayburn B. Randomized controlled trial of ventricular elastic support therapy in the treatment of symptomatic heart failure: rationale and design. Am Heart J. 2012 Nov; 164(5):638-45. PMID: 23137493.
      View in: PubMed
    4. Fang JC, DeMarco T, Givertz MM, Borlaug BA, Lewis GD, Rame JE, Gomberg-Maitland M, Murali S, Frantz RP, McGlothlin D, Horn EM, Benza RL. World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2012 Sep; 31(9):913-33. PMID: 22884380.
      View in: PubMed
    5. Costanzo MR, Ivanhoe RJ, Kao A, Anand IS, Bank A, Boehmer J, Demarco T, Hergert CM, Holcomb RG, Maybaum S, Sun B, Vassiliades TA, Rayburn BK, Abraham WT. Prospective evaluation of elastic restraint to lessen the effects of heart failure (PEERLESS-HF) trial. J Card Fail. 2012 Jun; 18(6):446-58. PMID: 22633302.
      View in: PubMed
    6. Can pulmonary arterial hypertension be diagnosed by an elevated pulmonary capillary wedge pressure outside of the guideline criteria? Barnett CF, De Marco T. Chest. 2011 Sep;140(3):828-9;.. Chest. Can pulmonary arterial hypertension be diagnosed by an elevated pulmonary capillary wedge pressure outside of the guideline criteria?. 2011; 3(140):828-9.
    7. Jensen BC, Swigart PM, Laden ME, DeMarco T, Hoopes C, Simpson PC. The alpha-1D Is the predominant alpha-1-adrenergic receptor subtype in human epicardial coronary arteries. J Am Coll Cardiol. 2009 Sep 22; 54(13):1137-45. PMID: 19761933.
      View in: PubMed
    8. McManus D, De Marco T. Pulmonary Hypertension. In Crawford M (ed): Current Diagnosis and Therapy: Cardiology, 3rd Edition, McGraw-Hill/Lange.2009; 352-70.
    9. Ghali JK, Boehmer J, Feldman AM, Saxon LA, Demarco T, Carson P, Yong P, Galle EG, Leigh J, Ecklund FL, Bristow MR. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Card Fail. 2007 Nov; 13(9):769-73. PMID: 17996827.
      View in: PubMed
    10. Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Pina IL, Fonarow GC, De Marco T, Pauly DF, Rogers J, DiSalvo TG, Butler J, Hare JM, Francis GS, Stough WG, O'Connor CM.Characterization and prognostic value of persistent hyponatreia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med. 2007.
    11. Lindenfeld J, Fledman AM, Saxon L, Boehmer J, Carson P, Ghali JK, Anand I, Singh S, Steinberg JS, Jaski B, De Marco T, Mann D, Yong P, Galle E, Ecklund F, Bristow M.Effects of cardiac resynchronization therapy with or without defibrillator on survival and hospitalization in patients with NYHA class IV heart failure. Circulation. 2007; 2(115):204-12.
    12. McGlothlin D, De Marco T. Perioperative Risk Assessment of Pulmonary Arterial Hypertension Patients Undergoing General Surgery. Advances in Pulmonary Hypertension 2007; 6(2):66-73.. 2007; 2(6):66-73.
    13. Elkayam U, Tasissa G, Binanay C, Wagoner L, Gheorghiade M, Warnica JW, Young J, Raybum BK, Rogers J, De Marco T, Leier CV.Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart Journal. 2007; (153):99-104.
    14. Ghali JK, Boehmer J, Feldman AM, Saxon LS, De Marco T, Carson P, Yong P, Galle EG, Leigh J, Ecklund FL, Bristow MR.J Card Fail. Influence of diabetes on cardiac resynchronizaiton therapy with or without defibrillator in patients with advanced heart failure. 2007; 9(13):769-73.
    15. Lindenfeld J, Feldman AM, Saxon L, Boehmer J, Carson P, Ghali JK, Anand I, Singh S, Steinberg JS, Jaski B, DeMarco T, Mann D, Yong P, Galle E, Ecklund F, Bristow M. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation. 2007 Jan 16; 115(2):204-12. PMID: 17190867.
      View in: PubMed
    16. De Marco T. Pulmonary Arterial Hypertension and Women. Cardiology Reviews .. 2006; 6(14):312-8.
    17. Galvao M, Kalman J, De Marco T, Fonarow GC, Galvin C, Ghali JK, Moskowitz RM and the ADHERE Scientific Advisory Committee, Investigators, Coordinators and Study Group.Gender Differences in In-Hospital Management and Outcomes in Patients with Decompensated Heart Failure: Analysis From the Acute Decompensated Heart Failure National Registry (ADHERE). J Cardiac Fail. 2006; 2(12):100-7.
    18. Oka RK, DeMarco T, Haskell WL. Effect of treadmill testing and exercise training on self-efficacy in patients with heart failure. Eur J Cardiovasc Nurs. 2005 Sep; 4(3):215-9. PMID: 15908277.
      View in: PubMed
    19. Mann MJ, Tseng E, Ratcliffe M, Strattman G, De Silva A, Demarco T, Achorn N, Moskalik W, Hoopes C. Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia. J Heart Lung Transplant. 2005 Feb; 24(2):222-5. PMID: 15701441.
      View in: PubMed
    20. Frost AE, Langleben D, Oudiz R, Hill N, Horn E, McLaughlin V, Robbins IM, Shapiro S, Tapson VF, Zwicke D, De Marco T, Schilz R, Rubenfire M, Barst RJ.The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol. 2005; 1(43):36-9.
    21. Oka RK, De Marco T, Haskell WL. Effect of treadmill testing and exercise training on self-efficacy in patients with heart failure. Eur J Cardiovasc Nurs .2005; 3(4):215-9.
    22. 8. De Marco T, Rapaport E. Cor pulmonale. In Mason RJ, Broaddus VC, Murray JF, Nadel JA (eds): Murray and Nadel's Textbook of Respiratory Medicine, 4th edition. Philadelphia: Saunders.2005; 1544-70.
    23. O’Connell JW, Schreck C, Moles M, Badhwar N, De Marco T, Olgin J, Lee B, Tseng Z, Kumar U, Botvinick EH .A unique method by which to quantitate synchrony with equilibrium radionuclide angiography. J Nucl Cardiol. 2005; 4(12):215-50.
    24. Mann MJ, Tseng E, Ratcliffe M, Strattman G, De Silva A, De Marco T, Achorn N, Moskalik W, Hoopes C. Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia. J Heart Lung Transplant .2005; 2(24):222-5.
    25. Nath J, De Marco T, Hourigan L, Heidenreich PA, Foster E.Correlation between right ventricular indices and clinical improvement in epoprostenol treated pulmonary hypertension patients. Echocardiography. 2005; 5(22):374-9.
    26. De Marco T, McGlothlin D. Managing Right Ventricular Failure in PAH. Advances in Pulmonary Hypertension.2005; 4(4):16-26.
    27. Choo DC, Huiskes B, Jones J, Fabbri S, Hawkins LA, Chatterjee K, De Marco T, Heywood JT. Amiodarone rescue therapy for severe decompensated heart failure initially unsuitable for beta-blockers. J Cardiovasc Pharmacol Ther 2003 Sep;8(3):187-92.2003; 3(8):187-92.
    28. Soran O, Fleishman B, De Marco T, Grossman W, Schneider VM, Manzo K, de Lame PA, Feldman AM. Enhanced External Counterpulsation in Patients With Heart Failure: A Multicenter Feasibility Study. Congest Heart Fail .2002; 4(8):204-8.
    29. Schwitter J, De Marco T, Kneifel S, Von Schulthess M, Jorg C, Arheden H, Ruhm S, Stumpf K, Buck A, Parmley WW, Luscher TF, Higgins C. Magnetic resonance-based assessment of global coronary flow and flow reserve and its relation to left ventricular functional parameters: a comparison with positron emission tomography. Circulation.2000; 23(101):269-72.
    30. Nanevicz T, Piette J, Zipkin D, Serlin M, Ennis S, De Marco T, Modin G. The feasibility of a telecommunication service in support of outpatient congestive heart failure care in a diverse patient population. Congest Heart Fail .2000; (6):140-5.
    31. Oka RK, De Marco T, Haskel WB, Botvinick E, Dae MW, Bolen K, Chatterjee K. Impact of a home-based walking and resistance training program on quality of life in patients with heart failure. Am J Cardiol .2000; 3(85):365-9.
    32. Kerwin WF, Botvinick EH, O’Connell JW, Merrick SH, De Marco T, Chatterjee K, Scheibly K, Saxon LA. Ventricular contraction abnormalities in dilated cardiomyopathy: Effect of biventricular pacing to correct interventricular dyssynchrony. J Am Coll Cardiol .2000; 5(35):1221-7.
    33. Missov E, De Marco T. Cor pulmonale. Cur Treat Options Cardiovasc Med.. 2000; (2):149-58.
    34. Missov E, De Marco T. Cor pulmonale. Current Treatment Options in Cardiovascular Medicine .. 2000; (2):149-58.
    35. Zellner C, Protter AA, Ko E, Pothireddy R, De Marco T, Hutchison SJ, Chou TM, Chatterjee K, Sudhir K. Coronary vasodilator effects of BNP: Mechanisms of action in coronary conductance and resistance arteries. Am J Physiol .1999; 45(276):H1049-57.
    36. Missov E, De Marco T. Clinical Insights on the use of highly sensitive cardiac troponin assays. Clin Chim Acta .. 1999; (284):175-85.
    37. Oka RK, De Marco T, Haskell WL. Perceptions of physical fitness in patients with heart failure. Progress in Cardiovasc Nursing.1999; 3(14):97-102.
    38. Schwitter J, De Marco T, Globits T, Sakuma H, Klinski C, Chatterjee K, Parmley WWP, Higgins CB. Influence of fenoldipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients: Possible interaction with cyclosporine medication. J Heart Lung Transplant.1999; (18):1003-13.
    39. De Marco T, Parmley WW. ß-adrenergic blockers in the management of heart failure. Western J Med .1998; 6(168):531.
    40. De Marco T, Chatterjee K. Phosphodiesterase inhibitors in refractory heart failure: Bridge to ß-blockade? J Am Coll Cardiol.1998; 6(31):1341-3.
    41. Chatterjee K, De Marco T. Management of Refractory Heart Failure. In Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJS (eds): Heart Failure Scientific Principles and Clinical Practice. New York, NY, Churchill Livingstone Inc.1997; 853-73.
    42. Shinbane JS, Chu E, De Marco T, Sobol Y, Fitzpatrick AP, Lau DM, Klinski C, Schiller J, Griffin JC, Chatterjee KC. Evaluation of acute dual-chamber pacing with a range of atrioventricular delays on cardiac performance in refractory heart failure. J Am Coll Cardiol .1997; (30):1295-1300.
    43. De Marco T, Goldman L. Predicting outcomes in severe heart failure. Editorial. Circulation .1997; 12(95):2597-9.
    44. Chou T, Sudhir K, Amidon T, Klinski C, De Marco T, Chatterjee K, Botvinick EH. Adenosine produces greater coronary hyperemic response in heart transplant recipients in comparison to dipyridamole. Am J Cardiol .1996; (78):908-13.
    45. De Marco T, Chatterjee, K. Refractory heart failure: A therapeutic approach. J Intensive Care Med .1996; (11):121-48.
    46. Sudhir K, De Marco T, Kumar S, Maganti K, Amidon TM, de Groot CJ, Klinski C, Lau D, Keith F, Taylor RN, et al. Transcoronary and pulmonary vascular dynamics of endothelin-1 in cardiac transplant recipients. J Heart Lung Transplant .1995; 2(14):230-6.
    47. Chatterjee K, De Marco T. Treatment of Symptomatic Heart Failure In Dhalla NS, Beamish RE, Takeda N, Nagano M (eds): The Failing Heart. New York, NY, Raven Press, Ltd. .1995; 337-53.
    48. Barbant SD, Redberg RF, Tucker KJ, Chatterjee K, De Marco T, Foster E, Schiller NB. Abnormal pulmonary artery pressure profile after cardiac transplantation: An exercise Doppler echocardiographic study. Am Heart J.1995; 6(129):1185-92.
    49. De Marco T, Keith F. Bridge to Cardiac Transplantation In Parmley WW, Chatterjee K, (eds): Cardiology. Philadelphia JB Lippincott Publishing Co., .1994; 7(3):1-21.
    50. Sudhir K, MacGregor JS, De Marco T, De Groot CJM, Taylor RN, Chou TM, Yock PG, Chatterjee K. Cyclosporin impairs release of endothelin derived relaxing factor in epicardial and resistance coronary arteries. Circulation .1994; 3018-23(90).
    51. Chatterjee K, Wolfe CL, De Marco T. Non-glycoside inotropes in congestive heart failure. Are they beneficial or harmful? Clinics of North America .. 1994.
    52. Cavero PG, Sudhir K, Galli F, De Marco T, Keith F, Chatterjee K. Effect of orthotopic cardiac transplantation on peripheral vascular function in congestive heart failure: Influence of cyclosporine therapy. Am Heart J .1994; 6(127):1581-7.
    53. Tucker K, Redberg R, Ploss D, De Marco T, Foster E, Schiller N. Noninvasive assessment of the pulmonary artery pressure response to exercise after uncomplicated heart transplantation. J Heart Lung Transplant 1993.1993; (12):604-12.
    54. Galli FC, Damon LE, Tomlanovich SJ, Keith F, Chatterjee K, De Marco T. Cyclosporine induced hemolytic uremic syndrome in a heart transplant recipient. J Heart Lung Transplant .. 1993; (12):440-4.
    55. Bersin RM, Kwasman M, Lau D, Klinski C, Tanaka K, Khorrami P, De Marco T, Wolfe CL, Chatterjee K. Importance of oxygen-hemoglobin binding to oxygen transport in congestive heart failure. British Heart J .1993; (70):443-7.
    56. Sudhir K, Fitzgerald P, MacGregor JA, De Marco T, Chatterjee K, Yock P. Transvenous coronary ultrasound imaging: A novel approach to visualization of the coronary arteries. Circulation .1991; (84):1957-61.
    57. Truit LC, Denaro CP, Lake JR, De Marco T. MR imaging of reversible cyclosporine-A neurotoxicity. AJNR .. 1991; (12):651-9.
    58. Hosenpud JD, De Marco T, Frazier OH, Griffith BP, Menkins AH, O'Connell JB, Olivari MT, Valentine HA. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Circulation .1991; (supp III):338-43.
    59. White M, Rouleau J-L, Ruddy TD, De Marco T, Moher D, Chatterjee K. Decreased coronary sinus oxygen content: A predictor of adverse prognosis in patients with severe heart failure. J Am Coll Cardiol .1991; (18):1631-7.
    60. Chatterjee K, De Marco T. Systemic and coronary hemodynamics and pharmacodynamics of enalapril and enalaprilat in congestive heart failure. Drugs .. 1990; 4(39):29-40.
    61. Stein MG, De Marco T, Gamsu G, Finkbeiner W, Golden JA. Computed tomography: Pathologic correlation in lung disease due to tocainide. Am Rev Respr Dis 1988; 137:458-60.1988; (137):458-60.
    62. Chatterjee K, De Marco T, Rouleau J-L. Vasodilator therapy in chronic congestive heart failure. Am J Cardiol 1988; 62:46A-54A.1988; (62):46A-54A.
    63. De Marco T, Chatterjee K. A patient with refractory congestive heart failure. The Complicated Cardivascular Patient. 1987; 1(2):20-31.1987; 2(1):20-31.
    64. De Marco T, Daly PA, Liu M, Kayser S, Parmley WW, Chatterjee K. Enalaprilat: A new parental angiotensin-converting enzyme inhibitor: Rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure. J Am Coll Cardiol 1987; 9:1131-38.1987; (9):1131-8.
    65. De Marco T, Chatterjee K. A patient with fatigue and jugular venous distention. The Complicated Cardiovascular Patient.1987; 3(1):9-12.
    66. Axelrod RD, De Marco T, Dae M, Botvinick EH, Chatterjee K. Hemodynamic and clinical evaluation of piroximone, a new inotrope-vasodilator agent, in severe congestive heart failure. J Am Coll Cardiol 1987; 9:1124-30.1987; (9):1124-30.
    67. Hansen RM, Viquerat C, Wiener-Kronish JP, De Marco T, Bahtia S, Marks JD, Botvinick EH, Chatterjee K, Matthay. Poor correlation between pulmonary arterial wedge pressure and left ventricular end-diastolic volume after coronary artery bypass graft surgery. Anesthesiology 1986; 64(6):764-70.1986; 6(64):764-70.